199 related articles for article (PubMed ID: 23001181)
1. Annotating MYC status with 89Zr-transferrin imaging.
Holland JP; Evans MJ; Rice SL; Wongvipat J; Sawyers CL; Lewis JS
Nat Med; 2012 Oct; 18(10):1586-91. PubMed ID: 23001181
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive
Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
[TBL] [Abstract][Full Text] [Related]
3. Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.
Doran MG; Carnazza KE; Steckler JM; Spratt DE; Truillet C; Wongvipat J; Sawyers CL; Lewis JS; Evans MJ
Mol Pharm; 2016 Feb; 13(2):683-8. PubMed ID: 26725682
[TBL] [Abstract][Full Text] [Related]
4. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
Henry KE; Dacek MM; Dilling TR; Caen JD; Fox IL; Evans MJ; Lewis JS
Clin Cancer Res; 2019 Jan; 25(1):166-176. PubMed ID: 30228208
[TBL] [Abstract][Full Text] [Related]
5. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
Ruggiero A; Holland JP; Hudolin T; Shenker L; Koulova A; Bander NH; Lewis JS; Grimm J
J Nucl Med; 2011 Oct; 52(10):1608-15. PubMed ID: 21908391
[TBL] [Abstract][Full Text] [Related]
6. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Doran MG; Watson PA; Cheal SM; Spratt DE; Wongvipat J; Steckler JM; Carrasquillo JA; Evans MJ; Lewis JS
J Nucl Med; 2014 Dec; 55(12):2045-9. PubMed ID: 25453051
[TBL] [Abstract][Full Text] [Related]
7. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system.
Heneweer C; Holland JP; Divilov V; Carlin S; Lewis JS
J Nucl Med; 2011 Apr; 52(4):625-633. PubMed ID: 21421727
[TBL] [Abstract][Full Text] [Related]
8. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
Aggarwal R; Behr SC; Paris PL; Truillet C; Parker MFL; Huynh LT; Wei J; Hann B; Youngren J; Huang J; Premasekharan G; Ranatunga N; Chang E; Gao KT; Ryan CJ; Small EJ; Evans MJ
Mol Cancer Res; 2017 Sep; 15(9):1221-1229. PubMed ID: 28592703
[TBL] [Abstract][Full Text] [Related]
9. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
[TBL] [Abstract][Full Text] [Related]
10. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.
Yang G; Goltsov AA; Ren C; Kurosaka S; Edamura K; Logothetis R; DeMayo FJ; Troncoso P; Blando J; DiGiovanni J; Thompson TC
Mol Cancer Res; 2012 Feb; 10(2):218-29. PubMed ID: 22144662
[TBL] [Abstract][Full Text] [Related]
12. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.
Vosjan MJ; Perk LR; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Nat Protoc; 2010 Apr; 5(4):739-43. PubMed ID: 20360768
[TBL] [Abstract][Full Text] [Related]
13. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
[TBL] [Abstract][Full Text] [Related]
15. Cerenkov luminescence imaging of medical isotopes.
Ruggiero A; Holland JP; Lewis JS; Grimm J
J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
[TBL] [Abstract][Full Text] [Related]
16. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.
Zeglis BM; Lewis JS
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741890
[TBL] [Abstract][Full Text] [Related]
17. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
Glumac PM; Gallant JP; Shapovalova M; Li Y; Murugan P; Gupta S; Coleman IM; Nelson PS; Dehm SM; LeBeau AM
Clin Cancer Res; 2020 Mar; 26(5):1054-1064. PubMed ID: 31732520
[TBL] [Abstract][Full Text] [Related]
18. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
19. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]